Eli Lilly and Company

Imclone LLC

Zymeworks Inc.

University of Washington

Immunogen, Inc.

Elanco US Inc.

Imclone Systems, Inc.

Actinium Pharmaceuticals, Limited

Zymeworks Bc Inc.

Dale Lincoln Ludwig

Yiwen Li

Yang Shen

Igor Edmondo Paolo D'Angelo

Gregory D Plowman

Yi Zhang

Juqun Shen

Vera Molkenthin

Michael Dewain Kalos

Hans K Erickson

Stephen R Plymate

Mark Berger

Paul J Balderes

Cheng Wang

Sandesh Seth

Keisha Thomas

Marshall Davenport Snavely

Douglas Bryan Burtrum

Scott W Eastman

Christopher M Moxham

Alan C Rigby

Igor Edmondo Paolo D'ANGELO

Radionuclide-labeled soluble biologics directed against peptide presenting Major Histocompatibility Complexes (pMHCs), and methods for treating cancers using the biologics are provided. Soluble biologics include recombinant T-cell receptor proteins (rTCR) and TCR-antibody mimics that specifically bind to pMHCs. The soluble biologics may further include a heavy chain of IgG1, IgG2, IgG4, or variants thereof. The radioisotopes used to label the soluble biologic may include alpha-emitting isotopes, such as actinium-225, or beta-emitting isotopes, such as lutetium-177, and may be administered at a maximum tolerated dose in a single bolus or in fractionated doses that together equal the maximum tolerated dose. The methods may further include administration of additional therapeutic agents or modalities.

Radioconjugates directed to MHC-complexed antigens in cancer

This invention provides a method for depleting a subject's hematopoietic stem cells comprising administering to the subject an effective amount of a radiolabeled anti-CD45 antibody, such asI-BC8 orAc-BC8. This invention also provides a method for treating a subject afflicted with a non-cancerous disorder treatable via genetically edited cell therapy comprising (i) administering to the subject an amount of a radiolabeled anti-CD45 antibody effective to deplete the subject's hematopoietic stem cells, and (ii) after a suitable time period, performing the therapy on the subject to treat the subject's disorder. Finally, this invention provides articles of manufacture for performing the subject methods.

Anti-CD45-based conditioning methods and uses thereof in conjunction with gene-edited cell-based therapies

The present invention relates to antibodies that are heterodimeric and bind human PD-L1 and human TIM-3, and may be useful for treating cancer alone and in combination with chemotherapy and other cancer therapeutics.

Anti-PD-L1-anti-TIM-3 bispecific antibodies

The present invention relates to antibodies that are heterodimeric and bind human PD-L1 and human PD-1, and may be useful for treating cancer alone and in combination with chemotherapy and other cancer therapeutics.

Checkpoint inhibitor bispecific antibodies

The present disclosure relates to anti-canine platelet derived growth factor receptor alpha antibodies binding to canine platelet derived growth factor receptor alpha.

Anti-canine platelet derived growth factor receptor alpha antibody

The present invention relates to antibodies that bind human programmed cell death 1 ligand 1 (PD-L1), and may be useful for treating solid and hematological tumors alone and in combination with chemotherapy and other cancer therapeutics.

PD-L1 antibodies

The invention provides conjugates that consist of a drug moiety agent and a cell binding agent that target human fibroblast growth factor receptor 3 (FGFR3). These conjugates have therapeutic use as they are designed and tailored to target a specific cell population and deliver a powerful cytotoxin inside the cell. The conjugate of the present invention has significant advantages over other conjugates known in the art by providing a targeted tumor therapy as well as bystander activity to neighboring cells in an important oncology receptor that is only moderately expressed.

Compounds to fibroblast growth factor receptor-3 (FGFR3) and methods of treatment

The present invention relates to a method of treating prostate cancer with androgen deprivation therapy and an insulin-like growth factor receptor (IGF-IR) antagonist. Although the response rate of prostate cancer to androgen deprivation therapy (ADT) is high, surviving cancer cells invariably become androgen independent (AI) and tumor growth follows. The invention inhibits or delays transition of androgen dependent cancer to androgen independent cancer, significantly decreases risk of recurrence, and improves treatment outcome.

IGF-IR antagonists as adjuvants for treatment of prostate cancer

This invention relates to human antibodies that bind to human insulin-like growth factor-1 receptor (IGF-IR), to derivatives of these antibodies (Fabs, single chain antibodies, bi-specific antibodies, or fusion proteins), and to uses of the antibodies and derivatives in therapeutic, and diagnostic methods. The invention relates to nucleic acids encoding the anti-IGF-IR, methods of generating the antibodies and expression. The invention further relates to combination therapies using ant-IGF-IR antibodies with anti-neoplastic drugs.

Fully human antibodies directed against the human insulin-like growth factor-1 receptor

This invention relates to human antibodies that bind to human insulin-like growth factor-1 receptor (IGF-IR), to derivatives of these antibodies (Fabs, single chain antibodies, bi-specific antibodes, or fusion proteins), and to uses of the antibodies and derivatives in therapeutic, and diagnostic methods. The invention relates to nucleic acids encoding the anti-IGF-IR, methods of generating the antibodies and expression. The invention further relates to combination therapies using ant-IGF-IR antibodies with anti-neoplastic drugs.

A substantially purified nucleic acid molecule comprising a VDUP1 promoter region, capable of directing expression of a polypeptide encoding sequence to which it is operably linked, whose expression is induced to maximal levels as a result of prolonged cell culture.

Growing community of inventors

Rockaway, NJ, United States of America

Dale Lincoln Ludwig